Abbott Laboratories

NYSE ABT

Download Data

Abbott Laboratories Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: 20.35

Abbott Laboratories Enterprise Value to EBITDA (EV/EBITDA) is 20.35 on June 03, 2024, a 1.26% change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Abbott Laboratories 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 24.64 on January 19, 2024, which is 21.08% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Abbott Laboratories 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 19.28 on April 12, 2024, which is -5.27% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Abbott Laboratories average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 21.63.
NYSE: ABT

Abbott Laboratories

CEO Mr. Robert B. Ford
IPO Date Jan. 13, 1978
Location United States
Headquarters 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
Employees 114,000
Sector Healthcare
Industry Medical devices
Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Similar companies

MDT

Medtronic PLC

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email